Drinking Glass Test for a Deadly Disease

Arkansas Association of Cancer Professionals

1 Session is Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Sunnie S. Kim, MD; Kellie D. Spector, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Syma Iqbal, MD; Benjamin Scheier, MD

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

North Carolina Oncology Association

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Washington State Medical Oncology Society

2 Sessions are Available!

Missouri Oncology Society

1 Session is Available!

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Lori A. Leslie, MD; Bachar Samra, MD

New Mexico Society of Clinical Oncology

3 Sessions are Available!

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Louisiana Oncology Society

2 Sessions are Available!

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Lori A. Leslie, MD; Jack W. Erter III, MD, MMHC

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Krish Patel, MD; Tara Graff, DO, MS

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Krish Patel, MD; Girish Kunapareddy, MD

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

Jae Park, MD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Krish Patel, MD; Matthew Ulrickson, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

ISGIO 2025: Early-Stage Colorectal Cancer

Kristen K. Ciombor, MD, MSCI; Stacey A. Cohen, MD; Eric D. Miller, MD, PhD; Van Karlyle Morris, MD; J. Joshua Smith, MD, PhD, FACS; Margaret Wheless, MD

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

Laura Dawson, MD, FRCPC, FASTRO; Thorvardur R. Halfdanarson, MD; Eileen M. O’Reilly, MD, FASCO; Scott Paulson, MD; Omair A. Shariq, MD, PhD; Aatur D. Singhi, MD, PhD; Alice C. Wei, MD, CM, MSc, FRCSC, FACS

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Post-Acute Sequelae of COVID-19 Infection Presenting With Neuropsychiatric Symptoms: Diagnosis and Management

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Amy E. Armstrong, MD; Phioanh “Leia” Nghiemphu, MD

Kansas Society of Clinical Oncology

1 Session is Available!

Satellite Symposia at the Annual Radiation Oncology Meeting

September 26-28, 2026

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Daniela A. Bota, MD, PhD; Kurt C. Demel, MD, MBA

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

The Optometry Meeting in Anaheim

October 1-2, 2026

Jersey City Psychiatry

October 2-3, 2026

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Daniela A. Bota, MD, PhD; Benjamin Scheier, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Tennessee Oncology Practice Society

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Kamel Abou Hussein, MD; Kimberly Ku, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Sara A. Hurvitz, MD, FACP; Milana Dolezal, MD, MSci

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Nevada Oncology Society

Sara A. Hurvitz, MD, FACP; Ajit K. Bisen, MD, MBA

Primary Care Education in Nashville

October 20-21, 2026

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Lori A. Leslie, MD; Alex Mejia, MD

Nevada Oncology Society

2 Sessions are Available!

5th Annual International Congress on Pediatric Oncology

November 6, 2026

Wyoming State Oncology Society

2 Sessions are Available!

Montana State Oncology Society

2 Sessions are Available!

Wisconsin Association of Hematology and Oncology

3 Sessions are Available!

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Rhode Island Oncology Society

2 Sessions are Available!

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Krish Patel, MD; Premila Malhotra, MD

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Lori A. Leslie, MD; Sushil Bhardwaj, MD, FACP

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; Neeta Pandit-Taskar, MD, MBA

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

ISGIO 2025: Advanced-Stage Colorectal Cancer

Cody Eslinger, MD, MS; Christopher Lieu, MD; Eric D. Miller, MD, PhD; Michael J. Overman, MD; Christina S. Wu, MD, MB, BCh

ISGIO 2025: Esophageal and Gastric Cancer

Joanna Mycek, MD; M. Bassam Sonbol, MD; Matthew R. Strickland, MD; Vivian E. Strong, MD, FACS

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Matthew Heeney, MD; Deepika S, Darbari, MD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Burden of Sickle Cell Disease

Matthew Heeney, MD; Biree Andemariam, MD

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Steven Fein, MD

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Biree Andemariam, MD; Nirmish Shah, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

Erin D. Michos, MD, MHS; Nihar Desai, MD, MPH

Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies

Onyema Ogbuagu, MD, FACP, FIDSA

Advances In™: A Glimpse Into the Future Care of Platinum-Resistant Ovarian Cancer

Alexander Olawaiye, MD; Alison Schram, MD

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Optimizing Multidisciplinary Care in TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

Ajai Chari, MD; Maria-Victoria Mateos, MD, PhD; Mohamad Mohty, MD, PhD

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Elias Jabbour, MD; Hagop Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire Roddie, MD, PhD

Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

Naval Daver, MD; Daniel A. Pollyea, MD; Gail J. Roboz, MD; Amer Zeidan, MBBS, MHS

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Advancements in Chronic Myeloid Leukemia: Treatment Strategies, Mechanisms, and Patient Management

Jorge E. Cortes, MD; Hagop Kantarjian, MD; Neil P. Shah, MD, PhD; Kendra Sweet, MD

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

Manish A. Shah, MD, FASCO; Syma Iqbal, MD; Haeseong Park, MD, MPH

Decoding HER2 Alterations in GEA: Best Practices for Testing and Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rondell P. Graham, MBBS; Tanios S. Bekaii-Saab, MD

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; Millie Das, MD

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS